Catherine Schulte
Stock Analyst at Baird
(3.34)
# 830
Out of 4,810 analysts
120
Total ratings
54.37%
Success rate
10.3%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Outperform | $161 → $159 | $103.12 | +54.19% | 15 | Feb 27, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Neutral | $9 → $3 | $1.73 | +73.41% | 5 | Feb 26, 2025 | |
| TECH Bio-Techne | Downgrades: Neutral | $88 → $68 | $51.07 | +33.15% | 10 | Feb 19, 2025 | |
| QGEN Qiagen | Downgrades: Neutral | $52 → $42 | $41.53 | +1.13% | 3 | Feb 19, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,362 → $1,369 | $1,046.58 | +30.81% | 7 | Feb 10, 2025 | |
| DHR Danaher | Maintains: Outperform | $268 → $258 | $189.92 | +35.85% | 7 | Jan 30, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $70 → $67 | $43.67 | +53.42% | 13 | Nov 6, 2024 | |
| AVTR Avantor | Maintains: Outperform | $27 → $26 | $15.40 | +68.83% | 10 | Oct 28, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $632 → $622 | $441.00 | +41.04% | 25 | Oct 24, 2024 | |
| CSTL Castle Biosciences | Maintains: Outperform | $42 → $38 | $21.05 | +80.52% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $39.50 | -16.46% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $74.59 | +276.73% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $323.44 | -32.91% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $151.74 | -86.82% | 1 | Jun 28, 2018 |
Agilent Technologies
Feb 27, 2025
Maintains: Outperform
Price Target: $161 → $159
Current: $103.12
Upside: +54.19%
Maravai LifeSciences Holdings
Feb 26, 2025
Downgrades: Neutral
Price Target: $9 → $3
Current: $1.73
Upside: +73.41%
Bio-Techne
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $51.07
Upside: +33.15%
Qiagen
Feb 19, 2025
Downgrades: Neutral
Price Target: $52 → $42
Current: $41.53
Upside: +1.13%
Mettler-Toledo International
Feb 10, 2025
Maintains: Neutral
Price Target: $1,362 → $1,369
Current: $1,046.58
Upside: +30.81%
Danaher
Jan 30, 2025
Maintains: Outperform
Price Target: $268 → $258
Current: $189.92
Upside: +35.85%
Exact Sciences
Nov 6, 2024
Maintains: Outperform
Price Target: $70 → $67
Current: $43.67
Upside: +53.42%
Avantor
Oct 28, 2024
Maintains: Outperform
Price Target: $27 → $26
Current: $15.40
Upside: +68.83%
Thermo Fisher Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $632 → $622
Current: $441.00
Upside: +41.04%
Castle Biosciences
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $21.05
Upside: +80.52%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $39.50
Upside: -16.46%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $74.59
Upside: +276.73%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $323.44
Upside: -32.91%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $151.74
Upside: -86.82%